Halozyme Therapeutics, Inc. (HALO) analyst actions
Rating and price-target actions on HALO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the HALO overview →
3 measured HALO analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE | Press release | -1.57% | +0.20% | |
| HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE | Press release | -2.44% | -6.15% | |
| Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance | Press release | -0.98% | -0.67% |
Keep exploring
More HALO: earnings → · SEC filings → · HALO overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Autolus Therapeutics plc - American Depositary Shares (AUTL) | 377 | -0.00% | 45% |
| Solid Biosciences Inc. (SLDB) | 375 | -0.17% | 46% |
| RITTER PHARMACEUTICALS (RTTR) | 374 | -0.61% | 37% |
| MIRAGEN THERAPEUTICS INC (MGEN) | 369 | -0.39% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.